Brief: NextCure And Simcere Zaiming Announce Expansion Of Ongoing Phase 1 Trial Of SIM0505 Into The US
16/10/2025 13:06
Oct 16 (Reuters) - NextCure Inc NXTC.O: NEXTCURE AND SIMCERE ZAIMING ANNOUNCE EXPANSION OF ONGOING PHASE 1 TRIAL OF SIM0505 (CDH6 ADC) INTO THE UNITED STATES NEXTCURE INC - TRIAL TO ACCELERATE PROOF-OF-CONCEPT DATA IN 1H 2026 Source text: ID:nGNX9m3yqn Further company coverage: NXTC.O
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660